|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 慢加急性肝衰竭的定义与临床诊断:东西方的异同显示文摘慢加急性肝衰竭(acute-on—chronicliverfailure,ACLF)是临床独特的肝病症候群,病情凶险,预后很差,病死率高。多年来,尽管各国学者对ACLF的定义、诱因、分类、诊断、治疗和预后判断等问题不断进行探索.但仍然难以形成统一的认识。 | 王福生 张政 吴娟 辛绍杰 Shiv K.Sarin | 2014 | 中华肝脏病杂志2014，22，7： | 15 |
| 2 | Combination of pegylated interferon and lamivudine for patients with chronic hepatitis B who have failed treatment显示文摘BACKGROUND: Treatment of chronic hepatitis B (CHB) alone with interferon or lamivudine alone or in combination is effective in only a small proportion of patients. Treatment of patients in whom antiviral therapy fails is challenging. This study was made to determine the efficacy of combined pegylated interferon alpha (peg-IFN) and lamivudine in patients with CHB who had failed to respond to antiviral treatment. METHODS: Twenty patients with CHB proven by liver biopsy, with ALT levels >1.5×ULN,HBV DNA levels>141 500 copies/ml, and previous treatment failure with an adequate regimen were treated with a combination of peg-IFN 1.5μg/kg and lamivudine 100 mg/day for 52 weeks and followed up for a further 24 weeks. Biochemical response was defined as normalization of ALT and DNA response as HBV DNA<141 500 copies/ml. Secondary efficacy measures included HBsAg loss, HBeAg loss and appearance of anti-HBe (in cases of HBeAg-positive patients). RESULTS: Twenty patients were treated, of whom 16 were HBeAg positive. At 52 weeks, normal ALT was seen in 10 (50%) (8 of 16 HBeAg+ and 2 of 4 HBeAg), HBV DNA response in 5 (25%) (5 of 16 in HBeAg+ and none in HBeAg-), and HBeAg loss with appearance of anti-HBe in 5 (31.3%) of the 16 HBeAg positive patients. At 76 weeks, 8 (80%) of the 10 patients with normal ALT at 52 weeks relapsed, with normal ALT only in 2 (10%) (1 of 16 HBeAg+ and 1 of 4 HBeAg-), and all 5 patients who had a DNA response at 52 weeks relapsed at 76 weeks and had no DNA response. HBeAg loss with appearance of anti-HBe was seen in 1 (6.3%) of 16 HBeAg-positive patients. None of the patients lost HBsAg. CONCLUSIONS: The combination of peg-IFN and lamivudine for 52 weeks is not effective for treatment of CHB patients with a failed treatment. New treatment strategies need to be developed. | Shiv K.Sarin Manoj Kumar Syed Hissar Barjesh C.Sharma | 2006 | Hepatobiliary & Pancreatic Diseases International2006，5，3： | 3 |
| 3 | The haemodynamic response to propranolol in cirrhosis with arterial hypertension: a comparative analysis with normotensive cirrhotic patients显示文摘 | P.Sharma A.Kumar S.Jha S. R.Mishra B. C.Sharma S. K.Sarin | 2010 | Alimentary Pharmacology & Therapeutics2010，，1： | 1 |
| 4 | Transmission of G145R mutant of HBV to an unrelated contact显示文摘 | VarshaThakur Syed N.Kazim Rajkumar C.Guptan Seyed E.Hasnain AngelineBartholomeusz V.Malhotra Shiv K.Sarin | 2005 | J Med Virol2005，，1： | 1 |
| 5 | Hepatic venous pressure gradient as a predictor of fibrosis in chronic liver disease because of hepatitis B virus显示文摘 | ManojKumar AshishKumar SyedHissar PankajJain ArchanaRastogi DeepakKumar PujaSakhuja Shiv K.Sarin | 2008 | Liver International2008，，5： | 1 |
| 6 | Basal core promoter, precore region mutations of HBV and their association with e antigen, genotype, and severity of liver disease in patients with chronic hepatitis B in India显示文摘 | RanjitChauhan Syed N.Kazim JayshreeBhattacharjee PujaSakhuja Shiv K.Sarin | 2006 | J Med Virol2006，，8： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员